Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCa…
| Métrica | REG1V.HE | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | 70.9% | 57.4% | +13.5% |
| Operating Margin | 23.2% | -34.4% | +57.6% |
| Net Margin | 15.9% | -32.5% | +48.3% |
| FCF Margin | 26.6% | -12.6% | +39.2% |
| ROE | 15.2% | -39.2% | +54.4% |
| ROA | 11.6% | -30.9% | +42.5% |
| Current Ratio | 2.05 | 2.73 | -0.68 |
| Debt / Equity | 0.01 | 0.28 | -0.27 |
| Tendencia (Piotroski) | FY25 | FY24 |
|---|---|---|
| ✓Rentabilidad sobre activos positiva | 11.6% | — |
| ✓Flujo de caja operativo positivo | €30M | €24M |
| ✗Rentabilidad sobre activos al alza | 11.6% | 13.1% |
| ✓Caja operativa/activos supera al ROA | 20.1% | ROA 11.6% |
| ✓Menos deuda a largo plazo | 1.1% | 4.1% |
| ✗Mejor liquidez (ratio corriente) | 2.05 | 2.18 |
| ✗Sin aumentar el nº de acciones | — | — |
| ✓Margen bruto al alza | 70.9% | 70.5% |
| ✗Rotación de activos al alza | 0.73 | 0.73 |
| Calidad del negocio | FY25 |
|---|---|
| ✓Margen FCF > 10 % | 26.6% |
| ✓ROCE > 10 % | 20.4% |
| ✗Ventas > 5 %/año (3 años) | 4.2% |
| ✓Deuda neta/EBITDA < 3x | Caja neta |
| ✗Reinversión (I+D + capex) > 3 % de ventas | 1.0% |
Riesgo de quiebra (Altman Z 8.7): zona segura
Revenio Group Oyj cotiza a 11.48 EUR y tiene una capitalización bursátil de €399M. Datos fundamentales de los informes financieros anuales oficiales (ESEF) vía filings.xbrl.org; cuentas anuales, sin trimestrales.Más empresas del sector Salud